Gregory S. Montgomery

Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study

Margaret Rosenfeld, Claire Wainwright, Mark Higgins et al. · The Lancet Respiratory Medicine · 2018 · 262 citations · Full text

Medicine, Cftr Gating Mutation, Pediatrics +1

Recombinant human VEGF treatment enhances alveolarization after hyperoxic lung injury in neonatal rats

Anette M. Kunig, Vivek Balasubramaniam, Neil Markham et al. · American Journal of Physiology-Lung Cellular and Molecular Physiology · 2005 · 204 citations

Acute Lung Injury, Inflammatory Lung Disease, Lung Inflammation +21

Official American Thoracic Society Technical Standards: Flexible Airway Endoscopy in Children

Robert E. Wood, Michael S. Schechter, Albin Leong et al. · American Journal of Respiratory and Critical Care Medicine · 2015 · 174 citations · Full text

Eicosapentaenoic acid is more effective than docosahexaenoic acid in inhibiting proinflammatory mediator production and transcription from LPS-induced human asthmatic alveolar macrophage cells

Timothy D. Mickleborough, Sandra Tecklenburg, Gregory S. Montgomery et al. · Clinical Nutrition · 2008 · 79 citations · Full text

Asthma, Inflammation, Docosahexaenoic Acid +12

Association of Antibiotics, Airway Microbiome, and Inflammation in Infants with Cystic Fibrosis

Jessica E. Pittman, Kristine M. Wylie, Kathryn Akers et al. · Annals of the American Thoracic Society · 2017 · 66 citations · Full text